The Dermatology Life Quality Index 1994-2007: A comprehensive review of validation data and clinical results

British Journal of Dermatology

Volumn 159, Issue 5, 2008, Pages 997-1035

  Basra, M K A ^a   Fenech, R ^b   Gatt, R M ^b   Salek, M S ^b   Finlay, A Y ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Dermatology Life Quality Index; DLQI; Outcome measures; Quality of life; Skin diseases; Validation

Indexed keywords

22 OXACALCITRIOL; ADALIMUMAB; ADAPALENE; ALEFACEPT; ALITRETINOIN; AZATHIOPRINE; BETAMETHASONE VALERATE; BOTULINUM TOXIN A; CICLOPIROXOLAMINE; CLOBETASOL PROPIONATE; CORTICOSTEROID; CYCLOSPORIN; DENILEUKIN DIFTITOX; EFALIZUMAB; ETANERCEPT; FEXOFENADINE; FOLIC ACID; HYDROCORTISONE; INFLIXIMAB; KETOCONAZOLE; LEFLUNOMIDE; LEVAMISOLE; LEVOCETIRIZINE; METHOTREXATE; PIMECROLIMUS; PYRITHIONE ZINC; RETINOIC ACID; SUCRALFATE; TACROLIMUS; UNINDEXED DRUG;

ACNE VULGARIS; ANUS PRURITUS; ATOPIC DERMATITIS; CHRONIC URTICARIA; CLINICAL TRIAL; DATA BASE; DERMATITIS; DERMATOLOGY; ECZEMA; HUMAN; HYPERHIDROSIS; MEDICAL RESEARCH; PRIORITY JOURNAL; PSORIASIS; PSYCHOMETRY; PUBLICATION; PYODERMA GANGRENOSUM; QUALITY OF LIFE; REVIEW; ROSACEA; SEBORRHEIC DERMATITIS; SUPPURATIVE HIDRADENITIS; VALIDATION PROCESS; VITILIGO;

HUMANS; PSYCHOMETRICS; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; SKIN DISEASES;

EID: 54249168036     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2008.08832.x     Document Type: Review

References (281)

1. Finlay AY, Ryan TJ. Disability and handicap in dermatology. Int J Dermatol 1996 35 : 305 11.
2. Jowett S, Ryan TJ. Skin disease and handicap: an analysis of the impact of skin conditions. Soc Sci Med 1985 20 : 425 9.
3. Anderson RT, Rajagopalan R. Development and validation of a quality of life instrument for cutaneous diseases. J Am Acad Dermatol 1997 37 : 41 50.
4. Chren MM, Lase RJ, Quin LM et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol 1996 107 : 707 13.
5. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994 19 : 210 16.
6. Morgan M, McCreedy R, Simpson J, Hay R. Dermatology Quality of Life Scales - a measure of the impact of skin diseases. Br J Dermatol 1997 136 : 202 6.
7. Evers AWM, Duller P, van de Kerkhof PCM et al. The Impact of Chronic Skin Disease on Daily Life (ISDL): a generic and dermatology-specific health instrument. Br J Dermatol 2008 158 : 101 8.
8. Le Cleach L, Chassany O, Levy A et al. Poor reporting of quality of life outcomes in dermatology randomized controlled clinical trials. Dermatology 2008 216 : 46 55.
9. Both H, Essink-Bot ME, Busschbach J, Nijsten T. Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol 2007 127 : 2726 39.
10. Lewis V, Finlay AY. 10 years' experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc 2004 9 : 169 80.
11. Mazzotti E, Picardi A, Sampogna F et al. Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasis. Br J Dermatol 2003 149 : 318 22.
12. Mazzotti E, Barbaranelli C, Picardi A et al. Psychometric properties of the Dermatology Life Quality Index (DLQI) in 900 Italian patients with psoriasis. Acta Derm Venereol (Stockh) 2005 85 : 409 13.
13. Hongbo Y, Thomas CL, Harrison MA et al. Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean? J Invest Dermatol 2005 125 : 659 64.
14. Loo W-J, Diba V, Chawla M, Finlay AY. Dermatology Life Quality Index: influence of an illustrated version. Br J Dermatol 2003 148 : 279 84.
15. Nunnally JC, Bernstein IH. Psychometric Theory. New York : McGraw-Hill, 1994.
16. McHorney CA. Ten recommendations for advancing patient-centered outcomes measurement for older persons. Ann Intern Med 2003 139 : 403 9.
17. Doward LC, Meads DM, Thorsen H. Requirements for quality of life instruments in clinical research. Value Health 2004 7 (Suppl. 1 S13 16.
18. Gorsuch RL. Factor Analysis, 2nd edn. Hillsdale, NJ : Lawrence Erlbaum, 1983.
19. Streiner DL. Figuring out factors: the use and misuse of factor analysis. Can J Psychol 1994 39 : 135 40.
20. Streiner DL, Norman GR. Health Measurement Scales: A Practical Guide to their Development and Use, 3rd edn. Oxford : Oxford University Press, 2003.
21. Tennant A, McKenna SP, Hagell P. Application of Rasch analysis in the development and application of quality of life instruments. Value Health 2004 7 (Suppl. 2 S22 6.
22. Kent G, Al-Abadie M. Factors affecting responses on Dermatology Life Quality Index items among vitiligo sufferers. Clin Exp Dermatol 1996 21 : 330 3.
23. Mørk C, Wahl A, Moum T. The Norwegian version of the Dermatology Life Quality Index: a study of validity and reliability in psoriatics. Acta Derm Venereol (Stockh) 2002 82 : 347 51.
24. Aghaei S, Sodaifi M, Jafari P et al. DLQI scores in vitiligo: reliability and validity of the Persian version. BMC Dermatol 2005 4 : 8.
25. Wallenhammar LM, Nyfjall M, Lindberg M, Meding B. Health-related quality of life and hand eczema - a comparison of two instruments, including factor analysis. J Invest Dermatol 2004 122 : 1381 9.
26. Wang XL, Zhao TE, Zhang XO. Assessment on the reliability and validity of the Dermatology Life Quality Index in Chinese version. Zhonghau Liu Xing Bing Xue Za Zhi 2004 25 : 791.
27. Öztürkcan S, Ermertcan AT, Eser E, Şahin MT. Cross validation of the Turkish version of Dermatology Life Quality Index. Int J Dermatol 2006 45 : 1300 7.
28. Takahashi N, Suzukamo Y, Nakamura M et al. Acne QoL Questionnaire Development Team. Japanese version of the Dermatology Life Quality Index: validity and reliability in patients with acne. Health Qual Life Outcomes 2006 4 : 46.
29. Nijsten T, Meads DM, de Korte J et al. Cross-cultural inequivalence of dermatology-specific health-related quality of life instruments in psoriasis patients. J Invest Dermatol 2007 127 : 2315 22.
30. Greenfield S, Nelson EC. Recent developments and future issues in the use of health status assessment measures in clinical setting. Med Care 1992 30 (Suppl. MS23 41.
31. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull 1979 86 : 420 8.
32. Kramer MS, Feinstein AR. Clinical biostatistics LII: the biostatistics of concordance. Clin Pharmacol Ther 1981 26 : 111 23.
33. Badia X, Mascaró JM, Lozano R. Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to change of the DLQI. Br J Dermatol 1999 141 : 698 702.
34. Jobanputra R, Bachmann M. The effect of skin diseases on quality of life in patients from different social and ethnic groups in Cape Town, South Africa. Int J Dermatol 2000 39 : 826 31.
35. Zachariae R, Zachariae C, Ibsen H et al. Dermatology Life Quality Index: data from Danish inpatients and outpatients. Acta Derm Venereol (Stockh) 2000 80 : 272 6.
36. Littenberg B, Partilo S, Licata A, Kattan MW. Paper Standard Gamble: the reliability of a paper questionnaire to assess utility. Med Decis Making 2003 23 : 480 8.
37. McKenna SP, Cook SA, Whalley D et al. Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials. Br J Dermatol 2003 149 : 323 31.
38. Reilly MC, Lavin PT, Kahler KH, Pariser DM. Validation of the Dermatology Life Quality Index and the Work Productivity and Activity Impairment - Chronic Hand Dermatitis questionnaire in chronic hand dermatitis. J Am Acad Dermatol 2003 48 : 128 30.
39. Kulthanan K, Jiamton S, Wanitphakdeedecha R, Chantharujikaphong S. The validity and reliability of the Dermatology Life Quality Index (DLQI) in Thais. Thai J Dermatol 2004 20 : 113 23.
40. Szepietowski J, Salomon J, Finlay AY et al. DLQI: Polish version. Dermatologia Kliniczna 2004 6 : 63 70.
41. Chuh AA, Chan HH. Effect on quality of life in patients with pityriasis rosea: is it associated with rash severity? Int J Dermatol 2005 44 : 372 7.
42. Ferraz LB, de Almeida FA, Vasconcellos MR et al. The impact of lupus erythematosus cutaneous on the quality of life: the Brazilian-Portuguese version of DLQI. Qual Life Res 2006 15 : 565 70.
43. Scientific Advisory Committee of the Medical Outcomes Trust. Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res 2002 11 : 193 205.
44. Cronbach LJ. Coefficient alpha and the internal-structure of tests. Psychometrika 1951 16 : 297 334.
45. Balkrishnan R, McMichael AJ, Camacho FT et al. Development and validation of a health-related quality of life instrument for women with melasma. Br J Dermatol 2003 149 : 572 7.
46. Finlay AY, Salek MS, Haney J. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology 2003 206 : 307 15.
47. Shikiar R, Bresnahan BW, Stone SP et al. Validity and reliability of patient reported outcomes used in psoriasis: results of two randomised clinical trials. Health Qual Life Outcomes 2003 1 : 53.
48. Lennox RD, Leahy MJ. Validation of the Dermatology Life Quality Index as an outcome measure for urticaria-related quality of life. Ann Allergy Asthma Immunol 2004 93 : 142 6.
49. Shikiar R, Harding G, Leahy M, Lennox RD. Minimal Important Difference (MID) of the Dermatology Life Quality Index (DLQI): results from patients with chronic idiopathic urticaria. Health Qual Life Outcomes 2005 3 : 36.
50. Shikiar R, Willian MK, Okun MM et al. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes 2006 4 : 71.
51. Chandrasena TG, Premaratna R, Muthugala MA et al. Modified Dermatology Life Quality Index as a measure of quality of life in patients with filarial lymphoedema. Trans R Soc Trop Med Hyg 2007 101 : 245 9.
52. Mazharinia N, Aghaei S, Shayan Z. Dermatology Life Quality Index (DLQI) scores in burn victims after revival. J Burn Care Res 2007 28 : 312 17.
53. Kirshner B, Guyatt G. A methodological framework for assessing health indices. J Chron Dis 1985 38 : 27 36.
54. Liang MH. Longitudinal construct validity: establishment of clinical meaning in patient evaluation instruments. Med Care 2000 38 (Suppl. 2 S84 90.
55. Fayers PM, Machin D. Scores and measurements: validity, reliability, sensitivity. In : Quality of Life: Assessment, Analysis and Interpretation. Chichester : Wiley, 2000.
56. Kurwa H, Finlay AY. Dermatology inpatient management greatly improves life quality. Br J Dermatol 1995 133 : 575 8.
57. Blackford S, Roberts DL, Salek MS, Finlay AY. Basal cell carcinomas cause little handicap. Qual Life Res 1996 5 : 191 4.
58. Newton JN, Mallon E, Klassen A et al. The effectiveness of acne treatment: an assessment by patients of the outcome of therapy. Br J Dermatol 1997 137 : 563 7.
59. Swartling C, Naver H, Lindberg M. Botulinum A toxin improves life quality in severe primary focal hyperhidrosis. Eur J Neurol 2001 8 : 247 52.
60. Mørk C, Wahl A. Improved quality of life among patients with psoriasis after supervised climate therapy at the Canary Islands. J Am Acad Dermatol 2002 47 : 314 16.
61. Campanati A, Penna L, Guzzo T et al. Quality of life assessment in patients with hyperhidrosis before and after treatment with botulinum toxin: results of an open-label study. Clin Ther 2003 25 : 298 308.
62. McPherson T. Impact on the quality of life of lymphoedema patients following introduction of a hygiene and skin care regimen in a Guyanese community endemic for lymphatic filariasis: a preliminary clinical intervention study. Filaria J 2003 2 : 1.
63. Menter A, Kosinski M, Bresnahan BW et al. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis. J Drugs Dermatol 2004 3 : 27 38.
64. Rhee JS, Matthews BA, Neuburg M et al. Skin cancer and quality of life: assessment with the Dermatology Life Quality Index. Dermatol Surg 2004 30 : 525 9.
65. Krueger GG, Langley RG, Finlay AY et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol 2005 153 : 1192 9.
66. Ongenae K, Dierckxsens L, Brochez L et al. Quality of life and stigmatization profile in a cohort of vitiligo patients and effect of the use of camouflage. Dermatology 2005 210 : 279 85.
67. Conroy FJ, Venus M, Monk B. A qualitative study to assess the effectiveness of laser epilation using a quality-of-life scoring system. Clin Exp Dermatol 2006 31 : 753 6.
68. Lachapelle J, Decroix J, Henrijean A et al. Desloratadine 5 mg once daily improves the quality of life of patients with chronic idiopathic urticaria. J Eur Acad Dermatol Venereol 2006 20 : 288 92.
69. Guyatt G, Walter S, Norman G. Measuring change over time: assessing the usefulness of evaluative instruments. J Chron Dis 1987 40 : 171 8.
70. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989 10 : 407 15.
71. Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol 2003 56 : 395 407.
72. Finlay AY. Current severe psoriasis and the Rule of Tens. Br J Dermatol 2005 152 : 861 7.
73. Halioua B, Beumont MG, Lunel F. Quality of life in dermatology. Int J Dermatol 2000 39 : 801 6.
74. Kaplan RM, Bush JW, Berry CC. Health status: types of validity and the index of well-being. Health Serv Res 1976 11 : 478 507.
75. Jenney ME, Campbell S. Measuring quality of life. Arch Dis Child 1997 77 : 347 54.
76. Cronbach LJ, Meehl PE. Construct validity in psychological tests. Psychol Bull 1955 52 : 281 302.
77. Nichol MB, Margoilies JE, Lippa E et al. The application of multiple quality of life instruments in individuals with mild-to-moderate psoriasis. Pharmacoeconomics 1996 10 : 644 53.
78. Herd RM, Tidman MJ, Ruta DA, Hunter JAA. Measurement of quality of life in atopic dermatitis: correlation and validation of two different methods. Br J Dermatol 1997 136 : 502 7.
79. Linnet J, Jemec GBE. An assessment of anxiety and dermatology life quality in patients with atopic dermatitis. Br J Dermatol 1999 140 : 268 72.
80. Lundberg L, Johannesson M, Silverdahl M et al. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol 1999 141 : 1067 75.
81. Mallon E, Newton JN, Klassen A et al. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol 1999 140 : 672 6.
82. Lundberg L, Johannesson M, Silverdahl M et al. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol (Stockh) 2000 80 : 430 4.
83. Schafer T, Staudt A, Ring J. German instrument for the assessment of quality of life in skin diseases (DIELH). Internal consistency, reliability, convergent and discriminant validity and responsiveness. Hautarzt 2001 52 : 624 8.
84. Kiebert G, Sorensen SV, Revicki D et al. Atopic dermatitis is associated with a decrement in health-related quality of life. Int J Dermatol 2002 41 : 151 8.
85. Augustin M, Wenninger K, Amon U et al. German adaptation of the Skindex-29 questionnaire on quality of life in dermatology: validation and clinical results. Dermatology 2004 209 : 14 20.
86. Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure. Arch Dermatol 2004 140 : 1513 19.
87. Sampogna F, Sera F, Abeni D. IDI Multipurpose Psoriasis Research on Vital Experience (IMPROVE) investigators. Measure of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis. J Invest Dermatol 2004 122 : 602 7.
88. Whalley D, McKenna SP, Dewar AL et al. A new instrument for assessing quality of life in atopic dermatitis: international development of the Quality of Life Index for Atopic Dermatitis (QoLIAD). Br J Dermatol 2004 150 : 274 83.
89. Wittkowski A, Richards HL, Griffiths CEM, Main CJ. The impact of psychological and clinical factors on quality of individuals with atopic dermatitis. J Psychosom Res 2004 57 : 195 200.
90. Yazici K, Baz K, Yazici A et al. Disease-specific quality of life is associated with anxiety and depression in patients with acne. J Eur Acad Dermatol Venereol 2004 18 : 435 9.
91. Zachariae R, Zachariae C, Ibsen HH et al. Psychological symptoms and quality of life of dermatology outpatients and hospitalized dermatology patients. Acta Derm Venereol (Stockh) 2004 84 : 205 12.
92. McKenna SP, Lebwhol M, Kahler KN. Development of the US PSORIQoL: a psoriasis-specific measure of quality of life. Int J Dermatol 2005 44 : 462 9.
93. Holm EA, Wulf HC, Stegmann H, Jemec GBE. Life quality assessment among patients with atopic eczema. Br J Dermatol 2006 154 : 719 25.
94. Basra MKA, Sue-Ho R, Finlay AY. The Family Dermatology Life Quality Index: measuring the secondary impact of skin disease. Br J Dermatol 2007 156 : 528 38.
95. Mozaffari H, Pourpack Z, Pourseyed S et al. Quality of life in atopic dermatitis patients. J Microbiol Immunol Infect 2007 40 : 260 4.
96. Schmitt JM, Ford DE. Role of depression in quality of life for patients with psoriasis. Dermatology 2007 215 : 17 27.
97. Swaine-Verdier A, Doward LC, Hagell P et al. Adapting quality of life instruments. Value Health 2004 7 (Suppl. 1 S27 30.
98. Jenner N, Campbell J, Marks R. Morbidity and cost of atopic eczema in Australia. Australas J Dermatol 2004 45 : 16 22.
99. Chan JJ, Gebauer K. Treatment of severe recalcitrant plaque psoriasis with single-dose intravenous tumour necrosis factor-alpha antibody (infliximab). Australas J Dermatol 2003 44 : 116 20.
100. Hachem JP, DePaepe K, Sterckx G et al. Evaluation of key biographical and clinical parameters of skin barrier function among hospital workers. Contact Dermatitis 2002 46 : 220 3.
101. Ongenae K, van Geel N, De Schepper S, Naeyaert JM. Effect of vitiligo on self-reported health-related quality of life. Br J Dermatol 2005 152 : 1165 72.
102. van Geel N, Ongenae K, Vander Haeghen Y et al. Subjective and objective evaluation of non-cultured epidermal cellular grafting for re-pigmenting vitiligo. Dermatology 2006 213 : 23 9.
103. Coghi S, Bortoletto MC, Sampaio SA et al. Quality of life is severely compromised in adult patients with atopic dermatitis in Brazil, especially due to mental components. Clinics 2007 63 : 235 42.
104. Solish N, Benohanian A, Kawalski JW. Prospective open-label study of botulinum toxin type A in patients with axillary hyperhidrosis: effects on function impairment and quality of life. Dermatol Surg 2005 31 : 405 13.
105. Jemec GBE, Wulf HC. Patient-physician consensus on quality of life in dermatology. Clin Exp Dermatol 1996 21 : 177 9.
106. Jemec GBE, Kynemund L. Time spent on treatment in dermatology - how much time do outpatients use and is it a measure of morbidity? Acta Dermatoven APA 2001 10 : 17 19.
107. Holm EA, Esmann S, Jemec GBE. Does visible atopic dermatitis affect quality of life more in women than in men? Gend Med 2004 1 : 125 30.
108. Holm EA, Esmann S, Jemec GBE. Patient education and morbidity in atopic eczema. Dermatol Nurs 2005 17 : 35 45.
109. Cvetkovski BS, Zachariae R, Jensen H et al. Prognosis of occupational hand eczema: a follow-up study. Arch Dermatol 2006 142 : 305 11.
110. Holm EA, Esmann S, Jemec GBE. The handicap caused by atopic dermatitis - sick leave and job avoidance. J Eur Acad Dermatol Venereol 2006 20 : 255 9.
111. Cvetkovski RS, Zachariae R, Jensen H et al. Quality of life and depression in a population of occupational hand eczema patients. Contact Dermatitis 2006 54 : 106 11.
112. El-Mongy S, El-Shahat FA, El-Bahaey W. Atopic dermatitis: relation between disease severity, anxiety and quality of life in children and adults. Egyptian Dermatol Online J 2006 2 : 1.
113. Lorette G, Ermosilla V. Clinical efficacy of a new ciclopiroxolamine/zinc pyrithione shampoo in scalp seborrheic dermatitis treatment. Eur J Dermatol 2006 16 : 558 64.
114. Poli F, Dreno B, Vershoores M. An epidemiological study of acne in female adults: results of a survey conducted in France. J Eur Acad Dermatol Venereol 2001 15 : 541 5.
115. Misery L, Finlay AY, Martin N et al. Atopic dermatitis: impact on the quality of life of patients and their partners. Dermatology 2007 215 : 123 9.
116. Schmitt J, Heese E, Wozel G, Meurer M. Effectiveness of inpatient treatment on quality of life and clinical disease severity in atopic dermatitis and psoriasis vulgaris - a prospective study. Dermatology 2007 214 : 68 76.
117. Hiltscher D, Boslet WT, Fuchslocher M et al. Quality of life in patients with rosacea and rhinophyma. Akt Dermatol 2001 27 : 391 4.
118. Schmid-Ott G, Burchard R, Niederauer HH et al. Stigmatization and quality of life of patients with psoriasis and atopic dermatitis. Hautarzt 2003 54 : 852 7.
119. Mayrshofer F, Hertl M, Sinkgraven R et al. Significant decrease in quality of life in patients with pemphigus vulgaris. Results from the German Bullous Skin Disease (BDS) Study Group. J Dtsch Dermatol Ges 2005 3 : 431 5.
120. Sunderkotter C, Weiss JM, Betermoller R et al. Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus: positive effects on major symptoms of atopic dermatitis and on quality of life. J Dtsch Dermatol Ges 2006 4 : 301 6.
121. Heinen-Kammerer T, Daniel D, Stratmann L et al. Cost-effectiveness of psoriasis therapy with etanercept in Germany. J Dtsch Dermatol Ges 2007 5 : 762 8.
122. Schöffski O, Augustin M, Prinz J et al. Cost and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multicentre study. J Dtsch Dermatol Ges 2007 5 : 209 18 (in German).
123. Czech W, Bräutigam M, Weidinger G, Schöpf F. A body-weight-independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life. J Am Acad Dermatol 2000 42 : 653 9.
124. Meurer M, Folster-Holst R, Wozel G et al. Primecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002 205 : 271 7.
125. Meurer M, Fartasch M, Albrecht G et al. Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology 2004 208 : 365 72.
126. Jacobi A, Antoni C, Manger B et al. Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 2005 52 : 522 6.
127. Weissenbacher S, Merkl J, Hildebrandt B et al. Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial. Br J Dermatol 2006 156 : 728 32.
128. Oppel T, Pavicic T, Kamann S et al. Pimecrolimus cream (1%) efficacy in perioral dermatitis - results of a randomized, double-blind, vehicle-controlled study in 40 patients. J Eur Acad Dermatol Venereol 2007 21 : 1175 80.
129. Reich K, Nestle FO, Wu Y et al. Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. Eur J Dermatol 2007 17 : 381 6.
130. Giess R, Naumann M, Werne E et al. Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2000 69 : 121 3.
131. Boehncke WH, Ochsendorf F, Paeslack I et al. Decorative cosmetics improve the quality of life in patients with disfiguring skin diseases. Eur J Dermatol 2002 12 : 577 80.
132. Hartmann A, Lurz C, Hamm H et al. Narrow-band UVB vs broad-band UVB therapy in combination with topical calcipotriol vs. placebo in vitiligo. Int J Dermatol 2005 44 : 736 42.
133. Staubach P, Onnen K, Vonend A et al. Autologous whole blood injections to patients with chronic urticaria and a positive autologous serum skin test: a placebo-controlled trial. Dermatology 2006 212 : 150 9.
134. Bechara FG, Gambichler T, Bader A et al. Assessment of quality of life in patients with primary axillary hyperhidrosis before and after suction-curettage. J Am Acad Dermatol 2007 56 : 207 12.
135. Augustin M, Zschocke I, Lange S et al. Quality of life in skin diseases: methodological and practical comparison of different quality of life questionnaires in psoriasis and atopic dermatitis. Hautarzt 1999 50 : 715 22.
136. Antoniou C, Stefanaki I, Stratigos A et al. The Greek experience with efalizumab in psoriasis from a university dermatologic hospital. Br J Dermatol 2007 156 (Suppl. 2 12 16.
137. Chaidemenos GC, Mourellou O, Avgoustinaki N et al. Intermittent vs. continuous 1-year cyclosporine use in chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2007 21 : 1203 8.
138. Babu BV, Nayak AN, Rath K, Kerketta AS. Use of the Dermatology Life Quality Index in filarial lymphoedema patients. Trans R Soc Trop Med Hyg 2006 100 : 258 63.
139. Godse KV. Quality of life in chronic urticaria. Indian J Dermatol 2006 51 : 155 7.
140. Agarwal S, Ramam M, Sharma VK et al. A randomized placebo-controlled double-blind study of levamisole in the treatment of limited and slowly spreading vitiligo. Br J Dermatol 2005 153 : 163 6.
141. Parsad D, Pandhi R, Dogra S et al. Dermatology Life Quality Index score in vitiligo and its impact on the treatment outcome. Br J Dermatol 2003 148 : 373 4.
142. Borimnejad L, Parsa Yekta Z, Nikbakht-Nasrabadi A, Firooz A. Quality of life with vitiligo: comparison of male and female Muslim patients in Iran. Gend Med 2006 2 : 124 30.
143. Rottem M, Elbirt D, Sthoeger Z, Desloratadine Study Group. Desloratadine for chronic idiopathic urticaria. Harefuah 2005 144 : 547 53.
144. Sampogna F, Tabolli S, Söderfeldt B et al. IDI Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) investigators. Measuring quality of life of patients with different clinical types of psoriasis using the SF-36. Br J Dermatol 2006 154 : 844 9.
145. Sampogna F, Gisondi P, Tabolli S, Abeni D. IDI Multipurpose Psoriasis Research on Vital Experiences investigations. Impairment of sexual life in patients with psoriasis. Dermatology 2007 214 : 144 50.
146. Nettis E, Colanardi MC, Paradiso MT, Ferrannini A. Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy 2004 4 : 1401 7.
147. Innocenzi D, Lupi F, Bruni F et al. Efficacy of a new aluminium salt thermophobic foam in the treatment of axillary and palmar primary hyperhidrosis: a pilot exploratory trial. Curr Med Res Opin 2005 21 : 1949 53.
148. Cassano N, Loconsole F, Galluccio A et al. Once-weekly administration of high-dosage etanercept in patients with plaque psoriasis: results of a pilot experience (power study). Int J Immunopathol Pharmacol 2006 19 : 225 9.
149. de Felice C, Mazzotta A, Esposito M et al. High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: efficacy, safety and impact on patient's quality of life. J Dermatol Treat 2006 17 : 355 8.
150. Vena GA, Cassano N, Colombo D et al. NEO-1-30 Study Group, Bari, Origio & Milan, Italy. Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol 2006 55 : 705 9.
151. Papoutsaski M, Chimenti MS, Costanzo A et al. Adalimumab for severe psoriasis and psoriatic arthritis: an open label study in 30 patients previously treated with other biologics. J Am Acad Dermatol 2007 56 : 269 75.
152. Campanati A, Bernardini ML, Gesuita R, Offidani A. Plantar focal idiopathic hyperhidrosis and botulinium toxin: a pilot study. Eur J Dermatol 2007 17 : 52 4.
153. Kondoh A, Ohta Y, Yamamoto K et al. Feasibility of modified DLQI-based questionnaire for evaluation of clinical efficacy of herbal medicine in chronic skin diseases. Tokai J Exp Clin Med 2005 30 : 97 102.
154. Yasuo K, Tetsuya M, Junko K et al. Topical sequential therapy using maxacalcitol ointment and corticosteroid in psoriasis vulgaris: with the entry of quality of life. Jpn J Clin Dermatol 2006 60 : 1178 85.
155. Matsuoka Y, Yoneda K, Sadahira C et al. Effects of skin care and makeup under instructions from dermatologists on the quality of life of female patients with acne vulgaris. J Dermatol 2006 33 : 745 52.
156. Won C, Seo P, Park Y et al. A multicentre trial of the efficacy and safety of 0.03% tacrolimus ointment for atopic dermatitis in Korea. J Dermatolog Treat 2004 15 : 30 4.
157. van Coevorden AM, van Sonderen E, Bouma J, Coenraads PJ. Assessment of severity of hand eczema: discrepancies between patient- and physician-rated scores. Br J Dermatol 2006 155 : 1217 22.
158. Nijsten T, Meads DM, McKenna SP. Dimensionality of the Dermatology Life Quality Index (DLQI): a commentary. Acta Derm Venereol (Stockh) 2006 86 : 284 5.
159. Polderman MC, Wintzen M, Cessie S, Pavel S. UVA-1 cold light therapy in the treatment of atopic dermatitis: 61 patients treated in the Leiden University Medical Center. Photodermatol Photoimmunol Photomed 2005 21 : 93 6.
160. Tjioe M, Otero ME, van deKerkhof PCM, Gerritsen MJP. Quality of life in vitiligo patients after treatment with long-term narrowband ultraviolet B phototherapy. J Eur Acad Dermatol Venereol 2005 19 : 56 60.
161. Wahl AK, Mørk C, Lillehol BM et al. Changes in quality of life in persons with eczema and psoriasis after treatment in departments of dermatology. Acta Derm Venereol (Stockh) 2006 86 : 198 201.
162. Wahl AK, Mørk C, Hanestad BR, Helland S. Coping with exacerbation in psoriasis and eczema prior to admission in a dermatological ward. Eur J Dermatol 2006 16 : 271 5.
163. Mørk C, Ozek M, Wahl AK. Treatment or leisure? Climate therapy of patients with psoriasis and psoriatic arthritis Tidsskr Nor Laegeforen 2004 124 : 60 2.
164. Pchelintseva AO, Korotaeva TV, Godzenko AA et al. Results of leflunomide treatment of psoriatic arthritis. Ter Arkh 2007 79 : 22 8.
165. Al-Buainian H, Gamal H, Dela Cruz F et al. The impact of vitiligo on quality of life in patients from Jeddah, Saudi Arabia. J Pan-Arab League Dermatologists 2005 16 : 97 105.
166. Al-Robaee AA. Assessment of quality of life in Saudi patients with vitiligo in a medical school in Qassim province, Saudi Arabia. Saudi Med J 2007 28 : 1414 17.
167. Blanch J, Rousaud A, Martinez E et al. Factors associated with severe impact of lipodystrophy on the quality of life of patients infected with HIV-1. Clin Infect Dis 2004 38 : 1464 70.
168. de Tiedra AG, Mercadal J, Badia X et al. A method to select an instrument for measurement of HR-QOL for cross-cultural adaptation applied to dermatology. Pharmacoeconomics 1998 14 : 405 22.
169. Yahathugoda TC, Wickramasinghe D, Weerasooriya MV, Samarawickrema WA. Lymphoedema and its management in cases of lymphatic filariasis: the current situation in three suburbs of Matara, Sri Lanka, before the introduction of a morbidity-control programme. Ann Trop Med Parasitol 2005 99 : 501 10.
170. Maroti M, Ulff E, Wijma B. Quality of life before and 6 weeks after treatment in a dermatological outpatient treatment unit. J Eur Acad Dermatol Venereol 2006 9 : 1081 5.
171. Gånemo A, Sjöden PO, Johansson E et al. Health-related quality of life among patients with ichthyosis. Eur J Dermatol 2004 14 : 61 6.
172. Meding B, Wallenhammar L-M, Lindberg M, Nyfjall M. Health-related quality of life and hand eczema. Contact Dermatitis 2004 50 : 152 3.
173. Uttjek M, Dufaker M, Nygren L, Stenberg B. Determinants of quality of life in a psoriasis population in northern Sweden. Acta Derm Venereol (Stockh) 2004 84 : 37 43.
174. Piletta PA, Wirth S, Hommel L et al. Circulating skin-homing T cells in atopic dermatitis. Selective up-regulation of HLA-DR, interleukin-2R, and CD30 and decrease after combined UV-A and UV-B phototherapy. Arch Dermatol 1996 132 : 1171 6.
175. Asawanonda P, Nateetongrungsak Y. Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque-type psoriasis: a randomized, placebo-controlled study. J Am Acad Dermatol 2006 54 : 1013 18.
176. Mechri A, Amri M, Douarika AA et al. Psychiatric morbidity and quality of life in vitiligo: a case controlled study. Tunis Med 2006 84 : 632 5 (in French).
177. Belhadjali H, Amri M, Mecheri A et al. Vitiligo and quality of life: a case-control study. Ann Dermatol Venereol 2007 134 : 233 6 (in French).
178. Ilgen E, Derya A. There is no correlation between acne severity and AQOLS/DLQI scores. J Dermatol 2005 32 : 705 10.
179. Öztas P, Calikoglu E, Cetin I. Psychiatric test in seborrhoeic dermatitis. Acta Derm Venereol (Stockh) 2005 85 : 68 9.
180. Ermertcan AT, Temeltaş G, Deveci A et al. Sexual dysfunction in patients with psoriasis. J Dermatol 2006 3 : 772 8.
181. Thomson KF, Wilkinson SM, Sommer S, Pollock B. Eczema: quality of life by body site and the effect of patch testing. Br J Dermatol 2002 146 : 627 30.
182. Haynes M. Examining day-case and in-patient psoriasis care. Prof Nurse 2000 16 : 893 6.
183. Kernick D, Cox A, Powell R et al. A cost consequence study of the impact of a dermatology-trained practice nurse on the quality of life of primary care patients with eczema and psoriasis. Br J Gen Pract 2000 50 : 555 8.
184. Klassen AF, Newton JN, Mallon E. Measuring quality of life in people referred for specialist care of acne: comparing generic and disease-specific measures. J Am Acad Dermatol 2000 43 : 229 33.
185. Shum RW, Lawton S, Williams HC et al. The British Association of Dermatologists audit of atopic eczema management in secondary care. Phase 3: audit of service outcome. Br J Dermatol 2000 142 : 721 7.
186. Williams TL, May CR, Esmail A et al. Patient satisfaction with teledermatology is related to perceived quality of life. Br J Dermatol 2001 145 : 911 17.
187. Gradwell C, Thomas KS, English JS, Williams HC. A randomized controlled trial of nurse follow-up clinics: do they help patients and do they free up consultants' time? Br J Dermatol 2002 147 : 513 17.
188. Helbling I, Ferguson JE, McKenna M, Muston HL. Audit of admissions to dermatology beds in Greater Manchester. Clin Exp Dermatol 2002 27 : 519 22.
189. Coast J, Noble S, Nobel A et al. Economic evaluation of a general practitioner with special interests led dermatology service in primary care. BMJ 2005 331 : 1444 8.
190. David SE, Ahmed Z, Salek MS, Finlay AY. Does enough quality of life-related discussion occur during dermatology outpatient consultations? Br J Dermatol 2005 153 : 997 1000.
191. Katugampola RP, Hongbo Y, Finlay AY. Clinical management decisions are related to the impact of psoriasis on patient-rated quality of life. Br J Dermatol 2005 152 : 1256 62.
192. Salisbury C, Nobel A, Horrocks S et al. Evaluation of a general practitioner with special interest service for dermatology: randomised controlled trial. BMJ 2005 331 : 1441 3.
193. Baron SE, Morris PK, Dye L et al. The effect of dermatology consultations in secondary care on treatment outcome and quality of life in new adult patients with atopic dermatitis. Br J Dermatol 2006 154 : 942 9.
194. Finlay AY. Measures of the effect of severe atopic eczema on quality of life. J Eur Acad Dermatol Venereol 1996 7 : 149 54.
195. Harris A, Burge SM, Dykes PJ, Finlay AY. Handicap in Darier's disease and Hailey-Hailey disease. Br J Dermatol 1996 135 : 959 63.
196. Blackford S, Finlay AY, Roberts DL. Quality of life in Behçet's syndrome: 335 patients surveyed. Br J Dermatol 1997 136 : 293.
197. Poon E, Seed PT, Greaves MW, Kobza-Black A. The extent and nature of disability in different urticarial conditions. Br J Dermatol 1999 140 : 667 71.
198. Harlow D, Poyner T, Finlay AY, Dykes PJ. Impaired quality of life in adults with skin disease in primary care. Br J Dermatol 2000 143 : 979 82.
199. Hutchings CV, Shum KW, Gawkrodger DJ. Occupational contact dermatitis has an appreciable impact on quality of life. Contact Dermatitis 2001 45 : 17 20.
200. Williamson D, Gonzalez M, Finlay AY. The effect of hair loss on quality of life. J Eur Acad Dermatol Venereol 2001 15 : 137 9.
201. Hermansen SE, Helland CA, Finlay AY. Patients' and doctors' assessment of skin disease handicap. Clin Exp Dermatol 2002 27 : 249 50.
202. Horn HM, Tidman MJ. Quality of life in epidermolysis bullosa. Clin Exp Dermatol 2002 27 : 707 10.
203. Jayaprakasam A, Darvey A, Osborne G, McGibbon D. Comparisons of assessment of severity and quality of life in cutaneous disease. Clin Exp Dermatol 2002 27 : 306 8.
204. Zaghloul SS, Goodfield MJD. Objective assessment of compliance with psoriasis treatment. Arch Dermatol 2004 140 : 408 14.
205. Charman CR, Venn AJ, Williams H, Bigby M. Measuring atopic eczema severity visually. Arch Dermatol 2005 141 : 1146 51.
206. Moloney FJ, Keane S, O'Kelly P et al. The impact of skin disease following renal transplantation on quality of life. Br J Dermatol 2005 153 : 574 8.
207. Shah M, Coates M. An assessment of the quality of life in older patients with skin disease. Br J Dermatol 2005 154 : 150 3.
208. Zaghloul SS, Cunliffe WJ, Goodfield MJD. Objective assessment of compliance with treatments in acne. Br J Dermatol 2005 152 : 1015 21.
209. Holme SA, Anstey AV, Finlay AY et al. Erythropoietic protoporphyria in the UK: clinical features and effect on qualify of life. Br J Dermatol 2006 155 : 574 81.
210. Woolacott N, Hawkins N, Mason A et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006 10 : 1 233.
211. Eghlileb AM, Davies EEG, Finlay AY. Psoriasis has a major secondary impact on the lives of family members and partners. Br J Dermatol 2007 156 : 1245 50.
212. Wells M, Macmillan M, Raab G et al. Does aqueous or sucralfate cream affect the severity of erythematous radiation skin reaction? A randomised controlled trial. Radiother Oncol 2004 73 : 153 62.
213. Brooklyn TN, Dunnill MGS, Shetty A et al. Infliximab for the treatment of pyoderma gangrenosum: a randomized, double blind, placebo controlled trial. Gut 2006 55 : 505 9.
214. Cusack C, Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol 2006 154 : 726 9.
215. Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet 2006 367 : 839 46.
216. Salim A, Tan E, Ilchyshyn A, Berth-Jones J. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial. Br J Dermatol 2006 154 : 1169 74.
217. Smith CH, Jackson K, Bashir SJ et al. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study. Br J Dermatol 2006 155 : 160 9.
218. Al-Ghaniem R, Short K, Pullen LC et al. 1% hydrocortisone ointment is an effective treatment of pruritus ani: a pilot randomised controlled crossover trial. Int J Colorectal Dis 2007 22 : 1463 7.
219. Weatherhead SC, Wahie S, Reynolds NJ, Meggitt SJ. An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema. Br J Dermatol 2007 156 : 346 51.
220. Papadopoulos L, Bor R, Legg C. Coping with the disfiguring effects of vitiligo. Br J Med Psychol 1999 72 : 385 96.
221. Swan MC, Paes T. Quality of life evaluation following endoscopic transthoracic sympathectomy for upper limb and facial hyperhydrosis. Ann Chir Gynaecol 2001 90 : 157 9.
222. Holme SA, Beattie PE, Fleming CJ. Cosmetic camouflage advice improves quality of life. Br J Dermatol 2002 147 : 946 9.
223. Loo W-J, Lanigan SW. Laser treatment improves quality of life of hirsute females. Clin Exp Dermatol 2002 27 : 439 41.
224. Pittler MH, Armstrong NC, Cox A et al. Randomized, double-blind, placebo-controlled trial of autologous blood therapy for atopic dermatitis. Br J Dermatol 2003 148 : 307 13.
225. Woo PN, Hay IC, Ormerod AD. An audit of the value of patch testing and its effect on quality of life. Contact Dermatitis 2003 48 : 244 7.
226. Yones SS, Palmer RA, Garibaldinos TM et al. Randomized double-blind trial of treatment of vitiligo. Arch Dermatol 2007 143 : 578 84.
227. Vensel E, Hilley T, Trent J et al. Sustained improvement of the quality of life of patients with psoriasis after hospitalisation. J Am Acad Dermatol 2000 43 : 858 60.
228. Fivenson D, Arnold RJG, Kaniecki DJ et al. The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organisation. J Manag Care Pharm 2002 8 : 333 42.
229. Tan SR, Whitney DT. Pulsed dye laser treatment of rosacea improves erythema, symptomatology, and quality of life. J Am Acad Dermatol 2004 51 : 592 9.
230. Hahn BH, Melfi CA, Chuang TY et al. Use of the Dermatology Life Quality Index (DLQI) in a Midwestern US urban clinic. J Am Acad Dermatol 2001 45 : 44 8.
231. Gottlieb AB, Mease PJ, Jackson M et al. Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists' offices. J Dermatolog Treat 2006 17 : 279 87.
232. Hundley JL, Carroll CL, Lang W et al. Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life. J Am Acad Dermatol 2006 54 : 217 20.
233. Schmitt JM, Ford DE. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology 2006 213 : 102 10.
234. Garduno J, Bhosle MJ, Balkrishnan R, Feldman SR. Measures used in specifying psoriasis lesion(s), global disease and quality of life: a systematic review. J Dermatolog Treat 2007 18 : 223 42.
235. Bagel J, Garland WT, Breneman D et al. Administration of DAB 389 IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial. J Am Acad Dermatol 1998 38 : 938 44.
236. Thompson AK, Finn AF, Schoenwetter WF. Effect of 60 mg twice-daily fexofenadine HCl on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria. J Am Acad Dermatol 2000 43 : 24 30.
237. Drake L, Prendergast M, Maher R et al. The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis. J Am Acad Dermatol 2001 44 : S65 72.
238. Bergstrom KG, Arambula K, Kimball AB. Medication formulation affects quality of life: randomized single-blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis. Cutis 2003 72 : 407 11.
239. Ellis CN, Mordin MM, Adler EY. Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomised, placebo controlled phase II trial. Am J Clin Dermatol 2003 4 : 131 9.
240. Gottlieb AB, Matheson RT, Low N et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003 139 : 1627 32.
241. Leonardi CL, Powers JL, Matheson RT et al. Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003 349 : 2014 22.
242. Feldman SR, Menter A, Koo JY. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol 2004 150 : 317 26.
243. Gottlieb AB, Evans R, Li S et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004 51 : 534 42.
244. Feldman SR, Gordon KB, Bala M et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol 2005 152 : 954 60.
245. Feldman SR, Kimball AB, Krueger GG et al. Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial. J Am Acad Dermatol 2005 53 : 887 9.
246. Weiss SC, Nguyen J, Chon S, Kimball AB. A randomized controlled clinical trial assessing the effect of betamethasone valerate 0.12% foam on the short-term treatment of stasis dermatitis. J Drugs Dermatol 2005 4 : 339 45.
247. Elewski B, Leonardi C, Gottlieb AB et al. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis. Br J Dermatol 2007 156 : 138 42.
248. Moore A, Gordon KB, Kang S et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol 2007 56 : 598 603.
249. Spector SL, Shikiar R, Harding G et al. The effect of fexofenadine hydrochloride on productivity and quality of life in patients with chronic idiopathic urticaria. Cutis 2007 79 : 157 62.
250. Revicki DA, Willian MK, Menter MK et al. Impact of adalimumab on patient-reported outcomes: results from a phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat 2007 18 : 341 50.
251. Rhee JS, Matthews BA, Neuburg M et al. The skin cancer index: clinical responsiveness and predictors of quality of life. Laryngoscope 2007 117 : 399 405.
252. Grosshans E, Marks R, Mascaró JM et al. Evaluation of clinical efficacy and safety of adapalene 0.1% gel versus tretinoin 0.025% gel in the treatment of acne vulgaris, with particular reference to the onset of action and impact on quality of life. Br J Dermatol 1998 139 (Suppl. 52 26 33.
253. Ruzicka T, Larsen FG, Galewicz D et al. Oral alitretinoin (9-cis-retinoic acid) therapy for chronic hand dermatitis in patients refractory to standard therapy: results of a randomized, double-blind, placebo-controlled, multicenter trial. Arch Dermatol 2004 140 : 1453 9.
254. von der Werth JM, Jemec GBE. Morbidity in patients with hidradenitis suppurativa. Br J Dermatol 2001 144 : 809 13.
255. Ho VCY, Griffiths CEM, Berth-Jones J et al. Intermittent short courses of cyclosporin microemulsion for the long-term management of psoriasis: a 2 year cohort study. J Am Acad Dermatol 2001 44 : 643 51.
256. Touw CR, Hakkaart-van Roijen L, Verboom P et al. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol 2001 144 : 967 72.
257. Gordon KB, Papp KA, Hamilton TK et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003 290 : 3073 80.
258. Kaltwasser JP, Nash P, Gladman D et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomised, placebo-controlled clinical trial. Arthritis Rheum 2004 50 : 1939 50.
259. Menter A, Gordon K, Carey W et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005 141 : 31 8.
260. Ortonne JP, Shear N, Shumack S et al. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial (NCT 00256139). BMC Dermatol 2005 5 : 13.
261. van de Kerkhof PCM, Griffiths CEM, Christophers E et al. Alefacept in the treatment of psoriasis in patients for whom conventional therapies are inadequate. Dermatology 2005 211 : 256 63.
262. Gladman DD, Mease PJ, Cifaldi MA et al. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Ann Rheum Dis 2007 66 : 163 8.
263. Gordon K, Korman N, Frankel E et al. Efficacy of etanercept in an integrated multi-study database of patients with psoriasis. J Am Acad Dermatol 2006 54 (Suppl. 2 S101 11.
264. Reich K, Nestle FO, Papp K et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol 2006 154 : 1161 8.
265. Sampogna F, Chren MM, Melchi EF et al. The Italian Multipurpose Psoriasis Research on Vital Experience (IMPROVE) Study Group. Age, gender, quality of life and psychological distress in patients hospitalized with psoriasis. Br J Dermatol 2006 154 : 325 31.
266. Tyring S, Gottlieb A, Papp K et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006 367 : 29 35.
267. Krueger GG, Langley RG, Leonardi C et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007 356 : 580 92.
268. Shikiar R, Heffernan M, Langley RG et al. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. J Dermatolog Treat 2007 18 : 25 31.
269. Tyring S, Gordon KB, Poulin Y et al. Long-term safety and efficacy of 50 mg etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007 143 : 719 23.
270. Kapp A, Pichler WJ. Levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, parallel, multicentre study. Int J Dermatol 2006 45 : 469 74.
271. Ayyalaraju RS, Finlay AY, Dykes PJ et al. Hospitalization for severe skin disease improves quality of life in the United Kingdom and the United States: a comparative study. J Am Acad Dermatol 2003 49 : 249 54.
272. Ryoji T, Masatoshi I, Hironobu I et al. Improvement of QOL of vitiligo patients using make-up cosmetic to conceal hypopigmentation. Skin Res 2006 5 : 72 80.
273. Salek S, Roberts A, Finlay AY. The practical reality of using a patient-reported outcome measure in a routine dermatology clinic. Dermatology 2007 215 : 315 19.
274. Schmitt-Egenolf M. PsoReg - the Swedish registry for systemic psoriasis treatment: the registry's design and objectives. Dermatology 2007 214 : 112 17.
275. Frost MH, Reeve BB, Liepa AM et al. What is sufficient evidence for the reliability and validity of patient-reported outcome measures? Value Health 2007 10 (Suppl. 2 S94 105.
276. de Korte J, Mombers FMC, Sprangers MAG, Bos JD. The suitability of quality-of-life questionnaires for psoriasis research. Arch Dermatol 2002 138 : 1221 7.
277. Ware JE, Snow KK, Kosinski K, Gandek B. SF-36 Health Survey Manual and Interpretation Guide. Boston, MA : New England Medical Center, The Health Institute, 1993.
278. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983 67 : 361 70.
279. Berzon R, Hays RD, Shumaker SA. International use, application and performance of health-related quality of life instruments. Qual Life Res 1993 2 : 267 8.
280. Grob JJ. Why are quality of life instruments not recognised as reference measures in therapeutic trials of chronic skin diseases? J Invest Dermatol 2007 127 : 2299 301.
281. Clarke SA, Eiser C. The measurement of health-related quality of life (QoL) in paediatric clinical trials: a systematic review. Health Qual Life Outcomes 2004 2 : 66.